KYZATREX ® is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX ® is safe or effective in males younger than 18 years old. Improper use may affect bone growth ...

The US Food and Drug Administration (FDA) will require makers of prescription testosterone products to clarify the approved uses of these medications on the product label and add information about the ...

RALEIGH, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, is pleased to announce that the U.S. Food and Drug Administration (FDA) has implemented significant labeling changes for ...

Please provide your email address to receive an email when new articles are posted on . The FDA removed a warning about CV risk from testosterone product labels after a randomized trial showed no link ...

This article presents an evaluation of testosterone marketing practices around the period of the testosterone label warning by physician specialty and rural vs urban primary care service area. In ...

The Food and Drug Administration Tuesday issued labeling changes for all testosterone products, adding a warning to prescribers about the drug’s potential for abuse. The revised labels will also ...

To clarify how testosterone therapy may affect cardiovascular outcomes — which is especially important since many men are using it inappropriately for "age-related hypogonadism" as opposed to "classic ...

Testosterone is a naturally occurring steroid hormone. Despite its status as a steroid, prescription testosterone replacement ...

The FDA approved classwide labeling changes for all prescription testosterone products to alert prescribers to the abuse potential and serious adverse outcomes related to testosterone and anabolic ...